Kyongbo Pharmaceutical Co., Ltd. (214390) Price & Analysis

― Followers

214390 Stock Chart & Stats

₩5070.00

-₩90.00(-1.74%)

Aug 21, 2026

―

Day’s Range― - ―

52-Week Range₩4,700.00 - ₩9,300.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)40.58K

Market Cap

₩121.45B

Enterprise Value₩267.53K

Total Cash (Recent Filing)₩13.83B

Total Debt (Recent Filing)₩158.00B

Price to Earnings (P/E)24.8

Beta0.04

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)208.03

Shares Outstanding23,906,860

10 Day Avg. Volume34,061

30 Day Avg. Volume40,583

Financial Highlights & Ratios

PEG Ratio-7.87

Price to Book (P/B)0.95

Price to Sales (P/S)0.52

P/FCF Ratio-4.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

214390 FAQ

What was Kyongbo Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Kyongbo Pharmaceutical Co., Ltd. lowest stock price was ₩4700.00 and its highest was ₩9300.00 in the past 12 months.

What is Kyongbo Pharmaceutical Co., Ltd.’s market cap?

Kyongbo Pharmaceutical Co., Ltd.’s market cap is ₩121.45B.

When is Kyongbo Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Kyongbo Pharmaceutical Co., Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 88 days.

How were Kyongbo Pharmaceutical Co., Ltd.’s earnings last quarter?

Kyongbo Pharmaceutical Co., Ltd. released its earnings results on Aug 14, 2026. The company reported ₩124.388 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Kyongbo Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Kyongbo Pharmaceutical Co., Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kyongbo Pharmaceutical Co., Ltd. pay dividends?

Kyongbo Pharmaceutical Co., Ltd. pays a N/A dividend of ₩50 which represents an annual dividend yield of N/A. See more information on Kyongbo Pharmaceutical Co., Ltd. dividends here

What is Kyongbo Pharmaceutical Co., Ltd.’s EPS estimate?

Kyongbo Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kyongbo Pharmaceutical Co., Ltd. have?

Kyongbo Pharmaceutical Co., Ltd. has 23,906,860 shares outstanding.

What happened to Kyongbo Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Kyongbo Pharmaceutical Co., Ltd. reported an EPS of ₩124.388 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.744%.

Which hedge fund is a major shareholder of Kyongbo Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in KR:214390

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kyongbo Pharmaceutical Co., Ltd.

Established in 1987 and based in Asan, South Korea, Kyongbo Pharmaceutical Co., Ltd is a key player in the South Korean pharmaceutical market, primarily focusing on the production and distribution of active pharmaceutical ingredients (APIs). Its API offerings span general, cephalosporin, and anti-cancer categories. Beyond APIs, the company also supplies a range of finished pharmaceutical products, including prescription medications for anesthetic, cardiovascular, and digestive uses, as well as antibiotics, alongside its over-the-counter (OTC) drug portfolio. Kyongbo Pharmaceutical extends its reach internationally, exporting its goods to 30 countries worldwide. The company officially adopted its current name, Kyongbo Pharmaceutical Co., Ltd, in March 2002, having previously been known as Kyongbo Chemical Co. Ltd.